About NextVivo
NextVivo is a company based in Palo Alto (United States) founded in 2021 by Calvin Kuo, Mark Davis, and Adam Margolin. It operates as a HealthTech. NextVivo has raised $7.9 million across 1 funding round from investors including ARE, Khosla Ventures and Wilson Sonsini Goodrich & Rosati. The company has 8 employees as of December 31, 2022. NextVivo offers products and services including Immune Organoid Technology. NextVivo operates in a competitive market with competitors including Newcells Biotech, InSphero, Pandorum, Vivodyne and Adapsyn, among others.
- Headquarter Palo Alto, United States
- Employees 8 as on 31 Dec, 2022
- Founders Calvin Kuo, Mark Davis, Adam Margolin
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$7.9 M (USD)
in 1 rounds
-
Latest Funding Round
$7.9 M (USD), Series A
Dec 09, 2021
-
Investors
ARE
& 2 more
-
Employee Count
8
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NextVivo
NextVivo offers a comprehensive portfolio of products and services, including Immune Organoid Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Organoids are developed for drug testing and therapy.
Unlock access to complete
Unlock access to complete
Funding Insights of NextVivo
NextVivo has successfully raised a total of $7.9M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.9 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $7.9M
-
First Round
First Round
(09 Dec 2021)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2021 | Amount | Series A - NextVivo | Valuation | Khosla Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in NextVivo
NextVivo has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Khosla Ventures and Wilson Sonsini Goodrich & Rosati. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US
|
Founded Year | Domain | Location | |
|
Provider of legal services to technology and life science companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NextVivo
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NextVivo
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nextvivo Comparisons
Competitors of NextVivo
NextVivo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Newcells Biotech, InSphero, Pandorum, Vivodyne and Adapsyn, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Induced pluripotent stem cell-derived organoid models are developed for research.
|
|
| domain | founded_year | HQ Location |
Cell-based assays and 3D microtissues for drug screening are developed.
|
|
| domain | founded_year | HQ Location |
Regenerative medicine and 3D tissues are developed for therapeutic uses.
|
|
| domain | founded_year | HQ Location |
Developer of AI-based platform for lab-grown human tissues
|
|
| domain | founded_year | HQ Location |
Provider of computational tools for bacterial metabolomic and genomic data analysis
|
|
| domain | founded_year | HQ Location |
Scalable processes for organoid expansion are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about NextVivo
When was NextVivo founded?
NextVivo was founded in 2021.
Where is NextVivo located?
NextVivo is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Who is the current CEO of NextVivo?
Adam Margolin is the current CEO of NextVivo. They have also founded this company.
Is NextVivo a funded company?
NextVivo is a funded company, having raised a total of $7.9M across 1 funding round to date. The company's 1st funding round was a Series A of $7.9M, raised on Dec 09, 2021.
How many employees does NextVivo have?
As of Dec 31, 2022, the latest employee count at NextVivo is 8.
What does NextVivo do?
NextVivo is focused on the development of immune organoid technology for drug discovery and therapy testing. Holistic 3D models of healthy and diseased tissues are created, retaining key immune cell interactions. Solutions are applied to generate and test therapies for cancer, infections, and autoimmune disorders within human-derived models. The biotechnology sector is primarily targeted with innovative approaches to improve drug safety and efficacy.
Who are the top competitors of NextVivo?
NextVivo's top competitors include Newcells Biotech, InSphero and Vivodyne.
What products or services does NextVivo offer?
NextVivo offers Immune Organoid Technology.
Who are NextVivo's investors?
NextVivo has 3 investors. Key investors include ARE, Khosla Ventures, and Wilson Sonsini Goodrich & Rosati.